6:35 AM
 | 
Mar 22, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs. placebo (RR=0.70, 95% CI: 0.62, 0.78, p<0.0001).

Amarin Corp. plc (NASDAQ:AMRN) plans to submit an sNDA to FDA by the...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >